Feedback / Questions
AVZO-021 - Avenzo Therap
https://www.businesswire.com/news/home/20251211085624/en/Avenzo-Therapeutics-Presents-Initial-Results-from-the-Phase-12-Study-of-AVZO-021-a-Potential-Best-in-Class-CDK2-Inhibitor-at-the-2025-San-Antonio-Breast-Cancer-Symposium
Dec 11, 2025
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next